Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNP-2198 for first-line Helicobacter pylori eradication vs bismuth quadruple regimen
CTR20230576Phase 3Completed
- Sponsor
- Dano Pharmaceuticals
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rifasutenizol in Helicobacter pylori infection (2 arms), sponsored by Dano Pharmaceuticals. Primary endpoint: Helicobacter pylori eradication rate at 4–6 weeks after last dose by 13C-urea breath test. Started Feb 2023; status: completed.
02
Drugs
rifasutenizol
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on CTR20230576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230576.